9-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one | 101192-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: 9-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one
• 英文别名: ethyl 9-methyl-4-oxo-4H-quinolizine-3-carboxylate；ethyl 9-methyl-4-oxoquinolizine-3-carboxylate
• CAS: 101192-35-2
• 化学式: C₁₃H₁₃NO₃
• 分子量: 231.251
• InChiKey: KIVVHZVNDCYHIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one 生成 9-Methyl-4H-quinolizin-4-one-3-carboxylic acid
  参考文献：
  名称：

  KITAURA, JOSIXIKO;OKU, TEHRUO;XIRAI, XIDEHO;YAMAMOTO, XISAYUKI;XASIMOTO, +

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-二甲基吡啶 、 乙氧基甲叉丙二酸二乙酯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正庚烷 、 乙基苯 、 邻二甲苯 为溶剂， 反应 19.58h， 生成 9-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one
  参考文献：
  名称：

  [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE LA QUINOLIZIDINONE

  摘要：

  本发明涉及式(I)的螺环哌啶化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。

  公开号：

  WO2009051715A1

文献信息

• QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Chang Ronald K.

  公开号：US20100222355A1

  公开（公告）日：2010-09-02

  The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的螺环吡啶化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物治疗由M1受体介导的疾病。
• Quinolizidinone M1 receptor positive allosteric modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08258135B2

  公开（公告）日：2012-09-04

  The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式（I）的螺环吡啶化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病。
• QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Kuduk Scott D.

  公开号：US20120232076A1

  公开（公告）日：2012-09-13

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病。
• Quinolizidinone carboxamide M1 receptor positive allosteric modulators
  申请人：Kuduk Scott D.

  公开号：US08754220B2

  公开（公告）日：2014-06-17

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病。
• Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0157346B1

  公开（公告）日：1990-01-31